ライフサイエンスコーパス: erectile dysfunction

1 nitourinary complications, incontinence, and erectile dysfunction.

2 ssociation with penile fibrosis and eventual erectile dysfunction.

3 l testing in and pharmacologic management of erectile dysfunction.

4 5 with high specificity and is used to treat erectile dysfunction.

5 diated erectile tissue damage and subsequent erectile dysfunction.

6 wer administered dosage for the treatment of erectile dysfunction.

7 ence, renal disease, bladder dysfunction and erectile dysfunction.

8 cular diseases to pulmonary hypertension and erectile dysfunction.

9 lation between cigarette smoking and risk of erectile dysfunction.

10 age, respectively, relative to those without erectile dysfunction.

11 PDE V inhibitor that is used clinically for erectile dysfunction.

12 ment or prophylaxis exists for posttreatment erectile dysfunction.

13 1a (ABT-724) for the potential treatment of erectile dysfunction.

14 potential risk factor for the development of erectile dysfunction.

15 onent of therapy for men with depression and erectile dysfunction.

16 low quality of life contributes to or causes erectile dysfunction.

17 static hyperplasia are definitely related to erectile dysfunction.

18 This effect has led to its use for treating erectile dysfunction.

19 escribing an association between smoking and erectile dysfunction.

20 and it is this that contributes to or causes erectile dysfunction.

21 unction, and loss of the BK channel leads to erectile dysfunction.

22 836 had previously smoked, and 203 reported erectile dysfunction.

23 ion-making when confronted by a patient with erectile dysfunction.

24 the stroke and therefore had stroke-related erectile dysfunction.

25 and is effective in patients suffering from erectile dysfunction.

26 ABT-724 could be useful for the treatment of erectile dysfunction.

27 get for treating cardiovascular diseases and erectile dysfunction.

28 also associated with increased prevalence of erectile dysfunction.

29 potential new strategy for the treatment of erectile dysfunction.

30 egies may exist for gene-based treatments of erectile dysfunction.

31 utility of gene therapy for the treatment of erectile dysfunction.

32 lication of gene therapy to the treatment of erectile dysfunction.

33 in and Germany have suggested lower rates of erectile dysfunction.

34 Rho kinase inhibitor suitable for therapy of erectile dysfunction.

35 atic hypotension, sweating abnormalities, or erectile dysfunction.

36 be possible to identify patients at risk of erectile dysfunction.

37 ential alternate avenue for the treatment of erectile dysfunction.

38 ations include penile deformity and possible erectile dysfunction.

39 e-dependent smooth muscle disorders, such as erectile dysfunction.

40 Men 60 years of age with erectile dysfunction.

41 ibitor, is an orally effective treatment for erectile dysfunction.

42 effective and widely prescribed therapy for erectile dysfunction.

43 herapeutic intervention for the treatment of erectile dysfunction.

44 ctive, well-tolerated treatment for men with erectile dysfunction.

45 of 151 male patients (31.8%) reported severe erectile dysfunction.

46 ased food is associated with a lower risk of erectile dysfunction.

47 clinical endpoints: late rectal bleeding and erectile dysfunction.

48 raction, such as hypertension, glaucoma, and erectile dysfunction.

49 quency, urinary incontinence, proctitis, and erectile dysfunction.

50 ated with devastating complications, notably erectile dysfunction.

51 ients presented with urinary incontinence or erectile dysfunction.

52 One patient in each group reported erectile dysfunction.

53 pisodic dry eyes and mouth, hot flashes, and erectile dysfunction.

54 ion, implying unique approaches for treating erectile dysfunction.

55 ccess of PDE5 inhibitors in the treatment of erectile dysfunction.

56 ng would each result in 1 additional case of erectile dysfunction.

57 rted use of medications or other devices for erectile dysfunction.

58 emain a viable tertiary treatment option for erectile dysfunction.

59 such as asthma, cardiovascular diseases, and erectile dysfunction.

60 ibitors in patients with coexisting LUTS and erectile dysfunction.

61 denafil, etc.) are first-line treatments for erectile dysfunction.

62 -eye movement sleep behaviour disorder), and erectile dysfunction.

63 complication rates of incontinence (0%-8%), erectile dysfunction (0%-3%), and retrograde ejaculation

64 , 2.04-2.46), hypotension (3.23, 1.85-5.52), erectile dysfunction (1.30, 1.11-1.51), urinary dysfunct

65 ir forties had the greatest relative odds of erectile dysfunction, 2.74 (95% confidence interval (CI)

66 9 vs 12.2 per 100 person-years; P = .02) and erectile dysfunction (26.8 vs 19.2 per 100 person-years;

67 d ratio 1.03 [95% CI 0.88-1.21]; p=0.72) and erectile dysfunction (272 [1.86% per annum] vs 302 [2.14

68 32%; P: = .010) but less frequently reported erectile dysfunction (56% v 72%; P: = .048).

69 ations: hot flashes (70%), nausea (34%), and erectile dysfunction (81%).

70 e efforts being made to reduce posttreatment erectile dysfunction, a major morbidity of these therapi

71 3) but more likely to receive a diagnosis of erectile dysfunction (absolute risk, 5.9 vs 5.3 per 100

72 tudy entry, 2420 men (57%) reported incident erectile dysfunction after 5 years.

73 morbidities may have a significant impact on erectile dysfunction after CaP treatment.

74 ced mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI).

75 wer mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI).

76 d tools to enable personalized prediction of erectile dysfunction after prostate cancer treatment are

77 Tadalafil is used to treat erectile dysfunction after prostate cancer treatment, bu

78 Erectile dysfunction after radical therapy for CaP may b

79 ked at some time had a greater likelihood of erectile dysfunction (age-adjusted odds ratio = 1.42, 95

80 are causative factors in the pathogenesis of erectile dysfunction, although the effects of spacefligh

81 phosphodiesterase 5 inhibitor used to treat erectile dysfunction, ameliorates high glucose stimulati

82 iation between cigarette smoking and risk of erectile dysfunction among 7,684 Chinese men aged 35-74

83 The 5-year likelihood of posttreatment erectile dysfunction among patients who were initially p

84 as to quantify the prevalence of concomitant erectile dysfunction and active depression among patient

85 Erectile dysfunction and cardiovascular disease share th

86 e the foundation for the strong link between erectile dysfunction and cardiovascular disease.

87 els were used to evaluate the association of erectile dysfunction and cardiovascular disease.

88 etermine associations between stroke-related erectile dysfunction and cerebral ischaemic lesion sites

89 Erectile dysfunction and depression are highly associate

90 Concomitant erectile dysfunction and depression represent a signific

91 .5, 16.7), and the prevalence of concomitant erectile dysfunction and depression was 5.1% (95% CI: 2.

92 l treatment of tumors with NI often leads to erectile dysfunction and deteriorated quality of life.

93 A/Rho-kinase contributes to diabetes-related erectile dysfunction and down-regulation of eNOS in the

94 ng evidence for an association between LUTS, erectile dysfunction and ejaculatory dysfunction.

95 orts the link between metabolic syndrome and erectile dysfunction and highlights metabolic syndrome a

96 dities associated with prostatectomy, namely erectile dysfunction and incontinence.

97 s showed associations between stroke-related erectile dysfunction and lesion sites in the right occip

98 Erectile dysfunction and low testosterone levels frequen

99 o in improving erectile function in men with erectile dysfunction and low testosterone levels.

100 effects of sildenafil treatment in men with erectile dysfunction and mild-to-moderate comorbid depre

101 ic symptoms (constipation, urinary symptoms, erectile dysfunction and orthostatic hypotension) were n

102 elopment of: in vitro pathological models of erectile dysfunction and Peyronie's disease; a model of

103 odiesterase that is used clinically to treat erectile dysfunction and pulmonary arterial hypertension

104 tadalafil, which are drugs for treatment of erectile dysfunction and pulmonary hypertension.

105 inary incontinence, anastomotic contracture, erectile dysfunction and rectourethral fistula (RUF) for

106 ce of underlying cardiac disease in men with erectile dysfunction and reports indicating serious card

107 prostatectomy is associated with significant erectile dysfunction and some decline in urinary functio

108 afety and efficacy of vardenafil in men with erectile dysfunction and untreated mild depression.

109 tolerated and highly efficacious in men with erectile dysfunction and untreated mild major depression

110 ectomy, post-operative complications such as erectile dysfunction and urinary incontinence persist at

111 DE-5 inhibitor in men who seek treatment for erectile dysfunction and who do not have a contraindicat

112 ab infusion, a second patient had persistent erectile dysfunction, and a third patient died of a haem

113 rapeutic target for the treatment of asthma, erectile dysfunction, and atherosclerosis.

114 and infertility in women and loss of libido, erectile dysfunction, and infertility in men; they are g

115 isorders including congestive heart failure, erectile dysfunction, and inflammation.

116 failure like infertility, low testosterone, erectile dysfunction, and low bone mineral density.

117 Depressed men commonly have erectile dysfunction, and men with erectile dysfunction

118 apter, including fertility, gonadal failure, erectile dysfunction, and menstrual issues in SCD.

119 Proximal myopathy, erectile dysfunction, and myelosuppression precluded the

120 degree of curvature, the type of deformity, erectile dysfunction, and penile length are all characte

121 er symptoms may include depression, fatigue, erectile dysfunction, and reduced muscle strength/mass.

122 rome, sudden deafness, hepatorenal syndrome, erectile dysfunction, and so on.

123 Bowel continence, erectile dysfunction, and social life disturbance were n

124 Erectile dysfunction appears to be one of the earliest s

125 ival rate for unifocal disease, and rates of erectile dysfunction are dramatically lower than those s

126 only have erectile dysfunction, and men with erectile dysfunction are frequently depressed.

127 ng evidence that endothelial dysfunction and erectile dysfunction are linked.

128 etes genetic predisposition on cataracts and erectile dysfunction are primarily attributed to adiposi

129 risk factors for cardiovascular disease and erectile dysfunction are similar.

130 phosphodiesterase-5 inhibitor treatment for erectile dysfunction associated with antidepressant ther

131 going prostatectomy were more likely to have erectile dysfunction at 2 years (odds ratio, 3.46; 95% C

132 was 0.015 per person-year among men without erectile dysfunction at study entry and was 0.024 per pe

133 Among the 4247 men without erectile dysfunction at study entry, 2420 men (57%) repo

134 at study entry; of these men, 3816 (47%) had erectile dysfunction at study entry.

135 y and was 0.024 per person-year for men with erectile dysfunction at study entry.

136 comorbidities have been reported, including erectile dysfunction, atrial fibrillation, obstructive s

137 Men with erectile dysfunction before 1986 were 3.8 times more lik

138 0.008) for participants with first onset of erectile dysfunction (before 1986) at 60 or more, 50-59,

139 very 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003.

140 such as sildenafil are widely used to treat erectile dysfunction, but growing evidence supports impo

141 Injury of corpus cavernosa results in erectile dysfunction, but its treatment has been very di

142 argets that are amenable to gene therapy for erectile dysfunction, but rather in the safety, specific

143 nhibitors of PDE5 such as sildenafil correct erectile dysfunction by augmenting cGMP-mediated vascula

144 Erectile dysfunction can be devastating for men and for

145 ole of endothelium in the pathophysiology of erectile dysfunction, cardiovascular disease, and the me

146 Other comorbidities including erectile dysfunction, cardiovascular diseases should als

147 association is causal, an estimated 22.7% of erectile dysfunction cases (11.8 million cases) among Ch

148 antiandrogens and managing treatment-induced erectile dysfunction continue to benefit patients with p

149 of energy, depressed mood, decreased libido, erectile dysfunction, decreased muscle mass and strength

150 Erectile dysfunction, defined as the consistent inabilit

151 In patients with refractory erectile dysfunction, dexterous and motivated patients r

152 he International Index of Erectile Function (Erectile Dysfunction Domain) score >/= 4 points in >/= 5

153 tes, 477 (21%) used cannabis, 460 (21%) used erectile dysfunction drugs, 453 (20%) used cocaine, 280

154 The target for the oral erectile dysfunction drugs, phosphodiesterase type 5 (PD

155 D) risk factors measured in mid-life predict erectile dysfunction (ED) 25 years later.

156 he internal pudendal arteries among men with erectile dysfunction (ED) and a suboptimal response to p

157 to determine whether patients with vascular erectile dysfunction (ED) and no other clinical cardiova

158 Chronic heart failure (HF) and erectile dysfunction (ED) are 2 highly prevalent disorde

159 Erectile dysfunction (ED) carries an independent risk fo

160 Periodontitis and erectile dysfunction (ED) have been linked with cardiova

161 Pharmacologic treatments for erectile dysfunction (ED) have gained popularity among m

162 Erectile dysfunction (ED) is a common condition affectin

163 Erectile dysfunction (ED) is a common condition where me

164 Erectile dysfunction (ED) is a highly prevalent and ofte

165 Erectile dysfunction (ED) is common among men with CAD.

166 Erectile dysfunction (ED) is estimated to affect more th

167 Erectile dysfunction (ED) is recognized as a major publi

168 The predominant etiology for erectile dysfunction (ED) is vascular, but limited data

169 Combining 2 first-line treatments for erectile dysfunction (ED) or initiating other modalities

170 This study was designed to determine whether erectile dysfunction (ED) predicts cardiovascular diseas

171 hough there are plausible mechanisms linking erectile dysfunction (ED) with coronary heart disease (C

172 terase-5 inhibitor used for the treatment of erectile dysfunction (ED), on the QT interval.

173 accounts significantly for the prevalence of erectile dysfunction (ED).

174 degeneration of the cavernous nerve (CN) and erectile dysfunction (ED).

175 osis, which is relevant to the occurrence of erectile dysfunction (ED).

176 less legs syndrome (RLS) was associated with erectile dysfunction (ED).

177 ers, and both share common risk factors with erectile dysfunction (ED).

178 function tenderness, frequent urination, and erectile dysfunction [ED]) and measures of physical and

179 t and demand for clinical services regarding erectile dysfunction, epidemiologic data on sexual dysfu

180 Men (N=152, mean age=56 years) with erectile dysfunction for > or =6 months (mean=5.7 years)

181 tion therapy for ischemic and any stroke and erectile dysfunction for any stroke.

182 llel-group, double-blind study, 280 men with erectile dysfunction for at least 6 months and untreated

183 he technology used intraoperatively, induces erectile dysfunction for most men who undergo the proced

184 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes.

185 surgery), antiandrogen therapy management of erectile dysfunction, funding and legislation for resear

186 across all time points included depression, erectile dysfunction, gait abnormalities, hearing loss,

187 is to update the results of the only phase 1 erectile dysfunction gene transfer trial and based upon

188 logical conditions including asthma, cancer, erectile dysfunction, glaucoma, insulin resistance, kidn

189 treatment in the management of patients with erectile dysfunction (Grade: insufficient evidence to de

190 levels such as hot flushes, lack of libido, erectile dysfunction, gynecomastia and bone mineral dens

191 Erectile dysfunction has a negative impact on health-rel

192 with potential utility for the treatment of erectile dysfunction has been discovered, guided by the

193 Radiological imaging in the field of erectile dysfunction has diminished in importance over t

194 tive inhibitor of PDE5 used for treatment of erectile dysfunction, has been found to cause relaxation

195 ulatory relationships between depression and erectile dysfunction have been poorly characterized, a 1

196 s of gastrointestinal and urinary morbidity, erectile dysfunction, hip fractures, and additional canc

197 ) increases cGMP and is used widely to treat erectile dysfunction; however, its role in the heart and

198 andin alprostadil are effective for treating erectile dysfunction; however, options for managing othe

199 mild cognitive impairment (HR = 1.91-2.37), erectile dysfunction (HR = 2.13), motor symptoms (HR = 2

200 The incidence of erectile dysfunction (IIEF-5 <= 11) at 12 months after s

201 l morbidity and fewer hip fractures but more erectile dysfunction; IMRT compared with proton therapy

202 understanding of the cause and management of erectile dysfunction in CaP survivors.

203 synthase (eNOS) function is associated with erectile dysfunction in diabetes mellitus, but the exact

204 ldenafil is safe and efficacious in treating erectile dysfunction in diabetic patients.

205 etrospective questionnaire with questions on erectile dysfunction in different time periods.

206 il citrate is effective for the treatment of erectile dysfunction in men taking concomitant serotonin

207 n effective and well-tolerated treatment for erectile dysfunction in men with diabetes.

208 Sildenafil is efficacious for erectile dysfunction in men with mild-to-moderate depres

209 Common disturbances include erectile dysfunction in men, menstrual abnormalities in

210 a) is the most widely used drug for treating erectile dysfunction in men.

211 Sildenafil significantly improved erectile dysfunction in patients taking concomitant sero

212 Although no standard management of erectile dysfunction in prostate cancer (CaP) survivors

213 Although many studies have provided data on erectile dysfunction in specific settings, few studies h

214 excluded, the age-standardized prevalence of erectile dysfunction in the previous 3 months was 33%.

215 ot support daily use of tadalafil to prevent erectile dysfunction in these patients.

216 The prevalence of moderate or complete erectile dysfunction in this sample was 36.4% (95% confi

217 of poor morning erection, low sexual desire, erectile dysfunction, inability to perform vigorous acti

218 or on the individual preferences of men with erectile dysfunction, including ease of use, cost of med

219 Risks of erectile dysfunction, incontinence, and disease recurren

220 mplants for genitourinary reconstruction for erectile dysfunction, incontinence, and orchiectomy have

221 In men with erectile dysfunction, intracavernosal injection of alpro

222 Erectile dysfunction is a common medical problem affecti

223 Erectile dysfunction is a common problem, affecting more

224 Erectile dysfunction is a harbinger of cardiovascular cl

225 Erectile dysfunction is a neurovascular phenomenon that

226 Erectile dysfunction is a worldwide health issue that af

227 Erectile dysfunction is also strongly associated with a

228 diesterase-5 inhibitor (PDE5i) treatment for erectile dysfunction is associated with lower mortality

229 Improvement of erectile dysfunction is associated with marked improveme

230 Erectile dysfunction is attributable to numerous biologi

231 Erectile dysfunction is common after radical prostatecto

232 Erectile dysfunction is common among individuals with Pa

233 Erectile dysfunction is common in men with diabetes.

234 , gene-based strategies for the treatment of erectile dysfunction is consistent with the multifactori

235 the influence of CP/CPPS on the incidence of erectile dysfunction is scant.

236 y result in agents for the treatment of male erectile dysfunction (MED) with a lower incidence of PDE

237 ibitors such as 2a for potential use in male erectile dysfunction (MED).

238 mpounds demonstrated in vivo efficacy in dog erectile dysfunction models and are orally bioavailable.

239 applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addit

240 activity was associated with lower risk for erectile dysfunction (multivariable relative risk, 0.7 [

241 d with abdominal obesity, diabetes mellitus, erectile dysfunction, muscle weakness, and all-cause mor

242 Erectile dysfunction occurred frequently after all treat

243 ere not associated with moderate or complete erectile dysfunction (odds ratio = 1.3, 95% CI: 0.5, 3.1

244 rog in 23, 20, 38 and 23 percent of men with erectile dysfunction of neurogenic, vasculogenic, psycho

245 sequential double-blind studies of men with erectile dysfunction of organic, psychogenic, and mixed

246 stitutional, prospective studies in men with erectile dysfunction of vasculogenic, neurogenic, psycho

247 tain patients who already have some baseline erectile dysfunction or are not candidates for nerve-spa

248 (P < .001), urinary function (P = .003), and erectile dysfunction (P = .008); by 3 years, however, th

249 to enhance sex (p=0.0006), use of drugs for erectile dysfunction (p<0.0001), and 100% condom use (p<

250 lation between cigarette smoking and risk of erectile dysfunction (p(trend) = 0.005).

251 males with normal erection and five organic erectile dysfunction patients.

252 depression, orthostatic hypotension, urinary/erectile dysfunction, PD family history, and the prodrom

253 lockbuster status in the treatment of penile erectile dysfunction (PED).

254 disease, obstructive sleep apnoea syndrome, erectile dysfunction, periodontitis, inflammatory bowel

255 vailable for the management of patients with erectile dysfunction, Peyronie's disease, penile dysmorp

256 Erectile dysfunction rates are universally high after wh

257 (12-26 weeks) identified a group of men with erectile dysfunction receiving 5 to 200 mg/day of silden

258 Patients with erectile dysfunction receiving sildenafil and concomitan

259 f this work is to review the fundamentals of erectile dysfunction relevant to the postprostatectomy p

260 gression analysis showed that stroke-related erectile dysfunction remained associated with lesions of

261 to regulate SIM1, previously associated with erectile dysfunction: rs78677597 (Europeans) (p = 5.32 x

262 ased lesion analysis, the difference between erectile dysfunction scores before and after stroke was

263 as brain volumes and the difference between erectile dysfunction scores before and after stroke.

264 In 32 patients (61.5%) erectile dysfunction scores declined after the stroke an

265 Deterioration of erectile dysfunction scores was not associated with pati

266 Erectile dysfunction should be included as an outcome in

267 Erectile dysfunction should prompt investigation and int

268 prespecified AEs of interest-muscle-related, erectile dysfunction, sleep disturbance, and cognitive i

269 are multifactorial and include hypogonadism, erectile dysfunction, sperm abnormalities, and complicat

270 in the advent of PDE5 inhibitors that treat erectile dysfunction, such as Viagra, Levitra, and Ciali

271 ata linking lower urinary tract symptoms and erectile dysfunction suggest that lower urinary tract sy

272 We report that two widely-used drugs for erectile dysfunction, tadalafil and vardenafil, trigger

273 duced over 30 years ago for the treatment of erectile dysfunction, technological innovations have con

274 vent of oral medication for the treatment of erectile dysfunction the disease has garnered increasing

275 For men with either incident or prevalent erectile dysfunction, the hazard ratio was 1.45 (95% CI,

276 croenvironment and a reference for potential erectile dysfunction therapies.

277 oral erectogenic agents for the treatment of erectile dysfunction, there will always be patients who

278 nt, to assess and treat side-effects such as erectile dysfunction, to switch to less costly generic a

279 Conservative criteria were used to classify erectile dysfunction treatment response and nonresponse.

280 Sildenafil was strongly associated with erectile dysfunction treatment response.

281 Erectile dysfunction treatment should be considered a co

282 less adverse effects in humans when used for erectile dysfunction treatment.

283 nary retention (three [2%] vs one [<1%]) and erectile dysfunction (two [1%] vs three [1%]).

284 tonomic features (constipation, hypotension, erectile dysfunction, urinary dysfunction, and dizziness

285 The results were sensitive to variation of erectile dysfunction utilities, but cost per QALY gained

286 T vs no ADT and 1.35 (95% CI, 1.18-1.53) for erectile dysfunction vs no dysfunction.

287 and hypercholesterolemia, the odds ratio of erectile dysfunction was 1.41 (95% confidence interval (

288 ire; during the fourth biennial examination, erectile dysfunction was assessed with the Brief Male Se

289 After adjustment, incident erectile dysfunction was associated with a hazard ratio

290 rge cohort of men, the authors observed that erectile dysfunction was associated with a higher risk o

291 this question, the authors examined whether erectile dysfunction was associated with Parkinson's dis

292 Erectile dysfunction was diagnosed according to the Inte

293 The association between smoking and erectile dysfunction was evaluated in a cohort of 2,115

294 ts due to S repens were mild and infrequent; erectile dysfunction was more frequent with finasteride

295 Multivariate-adjusted odds ratios of erectile dysfunction were 1.27 (95% CI: 0.91, 1.77), 1.4

296 Cigarette smoking and erectile dysfunction were assessed by questionnaire.

297 estyle factors most strongly associated with erectile dysfunction were physical activity and leanness

298 ociated with the reproductive system (mostly erectile dysfunction) were reported disproportionately m

299 Obesity is a major risk factor for erectile dysfunction, whereby excess reactive oxygen spe

300 ica albuginea, is reserved for patients with erectile dysfunction who have not responded to medical t

301 nt of non-life threatening disorders such as erectile dysfunction, will be outlined.